Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
0.6800
+0.0030 (0.44%)
Aug 6, 2026, 10:35 AM EDT - Market open
Inovio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 | |
Revenue Growth | - | -69.99% | -73.83% | -91.89% | 478.24% | -76.05% |
Gross Profit | - | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 |
Selling, General & Admin | 31.54 | 32.68 | 37 | 47.58 | 90.19 | 53.75 |
Research & Development | 52.19 | 54.21 | 75.62 | 86.68 | 187.65 | 249.24 |
Other Operating Expenses | - | - | - | 10.51 | - | - |
Total Operating Expenses | 83.72 | 86.89 | 112.62 | 144.77 | 277.84 | 302.99 |
Operating Income | -83.72 | -86.82 | -112.4 | -143.94 | -267.57 | -301.22 |
Interest Income | 2.05 | 2.42 | 4.77 | 8.13 | 4.78 | 3.36 |
Interest Expense | - | - | -0.18 | -1.22 | -1.25 | -1.94 |
Other Non-Operating Income (Expense) | -3.26 | -0.54 | 0.56 | 1.91 | -15.77 | -3.87 |
Total Non-Operating Income (Expense) | -1.21 | 1.88 | 5.14 | 8.82 | -12.24 | -2.44 |
Pretax Income | -84.93 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income | -84.93 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income to Common | -84.93 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 56 | 47 | 27 | 22 | 20 | 17 |
Shares Outstanding (Diluted) | 56 | 47 | 27 | 22 | 20 | 17 |
Shares Change | 79.22% | 72.63% | 22.49% | 11.51% | 14.27% | 34.62% |
EPS (Basic) | -1.45 | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
EPS (Diluted) | -1.45 | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -83.57 | -88.92 | -104.56 | -124.69 | -217.18 | -216.94 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.50 | -1.90 | -3.85 | -5.62 | -10.92 | -12.47 |
Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | - | -132871.00% | -51616.90% | -17300.30% | -2607.35% | -16972.30% |
Profit Margin | - | -130000.00% | -49254.30% | -16239.90% | -2726.67% | -17109.90% |
FCF Margin | - | -136074.00% | -48019.10% | -14986.20% | -2116.34% | -12223.60% |
EBITDA | -80.73 | -83.83 | -109.27 | -140.44 | -262.08 | -296.49 |
EBITDA Margin | - | -128297.00% | -50179.50% | -16879.20% | -2553.80% | -16705.80% |
EBIT | -83.72 | -86.82 | -112.4 | -143.94 | -267.57 | -301.22 |
EBIT Margin | - | -132871.00% | -51616.90% | -17300.30% | -2607.35% | -16972.30% |